Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


House Health Reform Bill Nets $48 Bil. From Pharma - CBO

Executive Summary

The Congressional Budget Office has put a value on the net savings that would accrue to the federal government through drug rebate and discount provisions in the pending House health care reform bill: $48 billion over 10 years

You may also be interested in...

Killing Part D Rebates For Duals Could Cost Pharma Another $12 Billion

As health care reform approaches a House-Senate conference, there is speculation that pharma will commit more money in order to keep the door closed on broader rebates.

House Health Reform Bill Will Be Modified To Close Part D Donut Hole More Quickly

Speaker Pelosi holds press conference with AARP to announce revisions to the coverage gap provisions in the bill.

Part D Rebates: Defeat In Finance Committee May Set Key Precedent

Democratic Sen. Bill Nelson of Florida may have made a tactical error in bringing up an amendment to mandate drug rebates under Medicare Part D during the Senate Finance Committee's markup of health reform legislation

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts